Title : Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo.

Pub. Date : 2018 Jan

PMID : 29269566






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Further analysis demonstrated that treatment with Bortezomib sensitized TC cells to Vemurafenib via mitochondrial dysregulation and apoptosis of TC cells, as evidenced by the increase in the expression of p53, Noxa protein, the loss of mitochondrial membrane potential, cytochrome c release and Poly (ADP-ribose) polymerase cleavage. Bortezomib tumor protein p53 Homo sapiens